Skip to main content
Erschienen in: Tumor Biology 1/2014

01.01.2014 | Research Article

WWTR1 promotes cell proliferation and inhibits apoptosis through cyclin A and CTGF regulation in non-small cell lung cancer

verfasst von: Li Wang, Zhenhong Chen, Yajuan Wang, De Chang, Longxiang Su, Yinghua Guo, Changting Liu

Erschienen in: Tumor Biology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The Hippo pathway plays a major role in development and organ size control, and its dysregulation contributes to tumorigenesis. WWTR1 is a transcription coactivator acting downstream of the Hippo pathway. Recently, WWTR1 has been reported to be overexpressed in several human cancers including lung cancer. However, the molecular mechanism of WWTR1 regulating lung cancer aggressiveness remains ambiguous. In the present study, we analyzed the expression of WWTR1 in NSCLC cell lines and found that WWTR1 was overexpressed at both the mRNA and protein levels. Knockdown of WWTR1 by siRNA interference in A549 cells significantly inhibited cell proliferation and increased paclitaxel-induced apoptosis. On the other side, WWTR1 overexpression in HBE cell line promoted cell proliferation and inhibited apoptosis. In addition, we found that the decreased proliferation after siRNA treatment was due to cell cycle arrest. Further analysis showed that WWTR1 could induce cyclin A, connective tissue growth factor (CTGF) expression, and inhibit caspase3 cleavage. In conclusion, WWTR1 promotes malignant cell growth and inhibits apoptosis by cyclin A and CTGF regulation.
Literatur
1.
Zurück zum Zitat Chan SW, Lim CJ, Guo K, Ng CP, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008;68:2592–8.PubMedCrossRef Chan SW, Lim CJ, Guo K, Ng CP, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008;68:2592–8.PubMedCrossRef
2.
Zurück zum Zitat Huang W, Lv X, Liu C, Zha Z, et al. The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFbeta-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. J Biol Chem. 2012;287:26245–53.PubMedCrossRef Huang W, Lv X, Liu C, Zha Z, et al. The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFbeta-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition. J Biol Chem. 2012;287:26245–53.PubMedCrossRef
3.
Zurück zum Zitat Pan J, Li S, Chi P, Xu Z, et al. Lentivirus-mediated RNA interference targeting WWTR1 in human colorectal cancer cells inhibits cell proliferation in vitro and tumor growth in vivo. Oncol Rep. 2012;28:179–85.PubMed Pan J, Li S, Chi P, Xu Z, et al. Lentivirus-mediated RNA interference targeting WWTR1 in human colorectal cancer cells inhibits cell proliferation in vitro and tumor growth in vivo. Oncol Rep. 2012;28:179–85.PubMed
4.
5.
Zurück zum Zitat de Cristofaro T, Di Palma T, Ferraro A, Corrado A, et al. TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer. 2011;47:926–33.PubMedCrossRef de Cristofaro T, Di Palma T, Ferraro A, Corrado A, et al. TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer. 2011;47:926–33.PubMedCrossRef
6.
Zurück zum Zitat Zhao D, Zhi X, Zhou Z, Chen C. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis. 2012;33:59–67.PubMedCrossRef Zhao D, Zhi X, Zhou Z, Chen C. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis. 2012;33:59–67.PubMedCrossRef
7.
Zurück zum Zitat Xie M, Zhang L, He CS, Hou JH, et al. Prognostic significance of TAZ expression in resected non-small cell lung cancer. J Thorac Oncol. 2012;7(5):799–807.PubMedCrossRef Xie M, Zhang L, He CS, Hou JH, et al. Prognostic significance of TAZ expression in resected non-small cell lung cancer. J Thorac Oncol. 2012;7(5):799–807.PubMedCrossRef
8.
Zurück zum Zitat Zhou Z, Hao Y, Liu N, et al. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 2011;30(18):2181–6.PubMedCrossRef Zhou Z, Hao Y, Liu N, et al. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene. 2011;30(18):2181–6.PubMedCrossRef
9.
Zurück zum Zitat Desdouets C, Sobczak-Thepot J, Murphy M, Brechot C. Cyclin A: function and expression during cell proliferation. Prog Cell Cycle Res. 1995;1:115–23.PubMedCrossRef Desdouets C, Sobczak-Thepot J, Murphy M, Brechot C. Cyclin A: function and expression during cell proliferation. Prog Cell Cycle Res. 1995;1:115–23.PubMedCrossRef
10.
Zurück zum Zitat Reed SI. Control of the G1/S transition. Cancer Surv. 1997;29:7–23.PubMed Reed SI. Control of the G1/S transition. Cancer Surv. 1997;29:7–23.PubMed
11.
Zurück zum Zitat Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002;59:1317–26.PubMedCrossRef Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002;59:1317–26.PubMedCrossRef
12.
Zurück zum Zitat Noguchi T, Dobashi Y, Minehara H, Itoman M, et al. Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors. Am J Pathol. 2000;156:2135–47.PubMedCrossRef Noguchi T, Dobashi Y, Minehara H, Itoman M, et al. Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors. Am J Pathol. 2000;156:2135–47.PubMedCrossRef
14.
Zurück zum Zitat Pagano M, Draetta G. Cyclin A, cell cycle control, and oncogenesis. Prog Growth Factor Res. 1991;3:267–77.PubMedCrossRef Pagano M, Draetta G. Cyclin A, cell cycle control, and oncogenesis. Prog Growth Factor Res. 1991;3:267–77.PubMedCrossRef
15.
Zurück zum Zitat Zhao X, Yang W, Shi C, et al. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells. Tumor Biol. 2011;32(2):335–46.CrossRef Zhao X, Yang W, Shi C, et al. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells. Tumor Biol. 2011;32(2):335–46.CrossRef
16.
Zurück zum Zitat Takai N, Ueda T, Kira N, et al. Calcium/calmodulin-dependent kinase inhibitor induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells. Tumor Biol. 2012;33(4):1053–8.CrossRef Takai N, Ueda T, Kira N, et al. Calcium/calmodulin-dependent kinase inhibitor induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells. Tumor Biol. 2012;33(4):1053–8.CrossRef
17.
Zurück zum Zitat Lai D, Ho KC, Hao Y, et al. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011;71(7):2728–38.PubMedCrossRef Lai D, Ho KC, Hao Y, et al. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011;71(7):2728–38.PubMedCrossRef
18.
Zurück zum Zitat Chan SW, Lim CJ, Huang C, et al. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene. 2011;30(5):600–10.PubMedCentralPubMedCrossRef Chan SW, Lim CJ, Huang C, et al. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene. 2011;30(5):600–10.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Chu CY, Chang CC, Prakash E, Kuo ML. Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci. 2008;15:675–85.PubMedCrossRef Chu CY, Chang CC, Prakash E, Kuo ML. Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci. 2008;15:675–85.PubMedCrossRef
21.
Zurück zum Zitat Cui L, Zhang Q, Mao Z, et al. CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells. Tumor Biol. 2011;32(4)):721–8.CrossRef Cui L, Zhang Q, Mao Z, et al. CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells. Tumor Biol. 2011;32(4)):721–8.CrossRef
Metadaten
Titel
WWTR1 promotes cell proliferation and inhibits apoptosis through cyclin A and CTGF regulation in non-small cell lung cancer
verfasst von
Li Wang
Zhenhong Chen
Yajuan Wang
De Chang
Longxiang Su
Yinghua Guo
Changting Liu
Publikationsdatum
01.01.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1064-9

Weitere Artikel der Ausgabe 1/2014

Tumor Biology 1/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.